Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cancer stem cells can be therapeutic target.

EBCC 6 2008

15 - 19 Apr 2008

Published: 3 Dec 2008

Views: 15840

Rating:

Save

Dr. Angel Rodriguez

New drug shrinks breast cancer tumours significantly in just six weeks research shows that cancer stem cells can be therapeutic target.

Categories:
Breast
Drug development

Related Videos

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Metastatic bone disease: Importance of bone-targeted agents

Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert...

Metastatic bone disease: Importance of bone-targeted agents ( Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert Coleman - The University of Sheffield, Sheffield, UK )

Choosing Wisely in implementing prevention, screening and early detection...

Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda

Choosing Wisely in implementing prevention, screening and early detection programs in Africa ( Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda )

Overview of the management of HER2-low breast cancer patients

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Overview of the management of HER2-low breast cancer patients ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Updates on HER2-low breast cancer

Prof Sana Al Sukhun - University of Jordan, Amman, Jordan

Updates on HER2-low breast cancer ( Prof Sana Al Sukhun - University of Jordan, Amman, Jordan )

Novel antibody-drug conjugates (ADCs) technologies for management of mBC

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Novel antibody-drug conjugates (ADCs) technologies for management of mBC ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Survival outcomes in randomised controlled trials with first-line CDK4/6i in...

Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland

Survival outcomes in randomised controlled trials with first-line CDK4/6i in HR+/HER2-Ve breast cancer ( Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland )

Spindle cell lesions of the breast

Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland

Spindle cell lesions of the breast ( Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland )

Management of HER2 positive metastatic breast cancer treatment algorithm

Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA

Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )

More from ecancer